Varian RapidArc Technology Used with Novalis Tx System for First Time Outside U.S. to Treat Head and Neck Cancer Patient
Posted on: Tuesday, 21 April 2009, 07:00 CDT
Doctors at Inselspital, the Bern University Hospital, used the Novalis Tx platform from Varian and BrainLAB to treat a patient suffering simultaneous skin cancer of the nose and an aggressive nasopharyngeal cancer with image-guided IMRT (intensity modulated radiotherapy). The treatment was 'very satisfactory' and compared favourably with conventional treatment techniques, according to Professor
Rather than targeting tumors with radiation beams from fixed angles, the Novalis Tx unit with RapidArc capability rotates continuously around the patient performing radiotherapy or radiosurgery several times faster than is possible with conventional techniques.
"Our first case was particularly challenging due to the fact that two distinct tumor regions were to be treated using different dose prescriptions," said Professor Aebersold. "The treatment was very quick and we were very impressed by the excellent conformity and good sparing of organs at risk compared to standard IMRT."
"By delivering advanced RapidArc treatments on a gold standard platform such as a Novalis Tx, we were able to combine speed with extremely high precision, to minimize the possibility of movement during treatment, which is particularly important bearing in mind the larger doses we are using."
In summer 2008, Inselspital became the first hospital outside the U.S. to install a Novalis Tx and treatments began in the autumn. Professor Aebersold and his team now plan to explore further stereotactic radiosurgery and stereotactic body radiotherapy treatments, along with hypo-fractionation for fewer treatment sessions as well as techniques and treatments such as partial breast irradiation and frameless treatment of arteriovenous malformations.
Novalis Tx features very high dose delivery rates, which contributes to shorter treatment times. It also offers dynamic fine beam shaping and non-invasive, precise frameless patient positioning for rapid and more comfortable treatments, and allows multiple beam energies of up to 18 million volts for treating deep-seated tumors.
The Novalis Tx platform includes an On-Board Imager(TM) device for pinpointing the tumor and positioning the patient with millimeter precision. The platform's ExacTrac* room-based image-guidance system provides continual imaging during treatment to detect movement and support robotic adjustments in patient positioning. This enhances protection of surrounding healthy tissues while enabling clinicians to concentrate higher, more effective doses on tumors.
Editorial contact:
* Trademark of BrainLAB
About Varian Medical Systems
Varian Medical Systems, Inc., of
SOURCE Varian Medical Systems, Inc.
Source: PR Newswire
Related Articles
- Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
- Cancer Treatment Services of Casa Grande, Arizona, Begins Treating Cancer Patients Using Fast, Precise RapidArc(TM) Radiotherapy Technology
- Nursing Research Grants Available to Improve Treatment of Patients With Auto-Immune Diseases and Cancer
- Mary Washington Hospital Selects Patient Care Technology Systems' Automatic Patient and Asset Tracking Solution for Emergency Department
- MediCorp Selects Patient Care Technology Systems' Emergency Department Information System for Stafford Hospital Center
- Pro-Pharmaceuticals Announces Boston Medical Center Dosing Patients With DAVANAT(R) in Advanced Biliary Cancer Trial
- Pharmion Submits European Marketing Authorization Application for Satraplatin in Combination With Prednisone for the Treatment of Patients With Metastatic Hormone-Refractory Prostate Cancer Who Have Failed Prior Chemotherapy
- Docetaxel and Oxaliplatin Study Shows Promise As a Treatment for Patients With Gastroesophageal and/or Stomach Cancer
- AVAX Technologies Announces the Initiation of Its Clinical Study for the Treatment of Patients With Non Small Cell Lung Cancer
- AVAX Technologies Announces the Filing of IND for the Treatment of Patients With Non Small Cell Lung Cancer
User Comments (0)

RSS Feeds